Daily Dose Effects of Risperidone on Weight and Other Metabolic Parameters: A Prospective Cohort Study

Atypical antipsychotics can induce metabolic side effects, but whether they are dose-dependent remains unclear. To assess the effect of risperidone and/or paliperidone dosing on weight gain and blood lipids, glucose, and blood pressure alterations. Data for 438 patients taking risperidone and/or its metabolite (paliperidone) for up to 1 year were obtained between 2007 and 2018 from a longitudinal study monitoring metabolic parameters. For each milligram increase in dose, we observed a weight increase of 0.16% at 1 month of treatment ( = .002) and increases of 0.29%, 0.21%, and 0.25% at 3, 6, and 12 months of treatment, respectively ( < .001 for each). Moreover, dose increases of 1 mg raised the risk of a ≥ 5% weight gain after 1 month (OR = 1.18;  = .012), a strong predictor of important weight gain in the long term. When we split the cohort into age categories, the dose had an effect on weight change after 3 months of treatment (up to 1.63%,  = .008) among adolescents (age ≤ 17 years), at 3 (0.13%,  = .013) and 12 (0.13%,  = .036) months among adults (age > 17 and < 65 years), and at each timepoint (up to 1.58%,  < .001) among older patients (age ≥ 65 years). In the whole cohort, for each additional milligram we observed a 0.05 mmol/L increase in total cholesterol ( = .018) and a 0.04 mmol/L increase in LDL cholesterol ( = .011) after 1 year. Although of small amplitude, these results show an effect of daily risperidone dose on weight gain and blood cholesterol levels. Particular attention should be given to the decision of increasing the drug dose, and minimum effective dosages should be preferred.